Monday, March 10, 2025

Healthcare

Bright Minds Targets Epilepsy with Breakthrough 5-HT2C Agonist

Bright Minds Biosciences launches a Phase 2 trial for BMB-101, targeting drug-resistant epilepsy with high unmet needs. The company trades at a $5M market cap,...

A Closer Look at NurExone: Exosome Innovation with Long-Term Potential (TSXV: NRX, OTCQB: NRXBF)

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies. NurExone chose to base its...

CULT Food Science is Pioneering a New Era of Food Tech

CULT Food Science Corp. ("CULT" or the "Company") (CSE: CULT) (OTC: CULTF) (FRA: LN0) is a disruptive food technology platform pioneering the commercialization of lab-grown meat and...

3 SmallCap Stocks to Watch $OSTX $WCU $LVO

Always neat to introduce timely juniors with great potential. In this case, our constituents are OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"),...

OS Therapies Advances in Osteosarcoma Treatment

Successfully raised $6.4 million in IPO, securing operations through mid-2025. Prioritizing fast-tracked development of OST-HER2, a promising treatment for HER-2 positive osteosarcoma. Positioned to capitalize on...

Popular

Subscribe